Compare Cassava Sciences Inc (FLNA) vs Roblox Corp (RBLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Roblox Corp — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Roblox Corp trades at $56.34 (market cap $40.86B). The key difference: Roblox Corp is far larger — about 768.9× Cassava Sciences Inc's market cap, and Roblox Corp is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | RBLX | |
|---|---|---|
Market Cap | $53.14M | $40.86B |
Sector | Health | Media |
52-Week High | $4.64 | $141.56 |
52-Week Low | $1.09 | $41.30 |
Enterprise Value | -$33.43M | $39.45B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.
The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.
Roblox (RBLX) trades at $54.47, down 1.12% on the day, with a bullish technical signal from moving averages despite neutral oscillators. The company shows strong revenue growth, reaching $4.89B in 2025, but continues to report significant net losses (-$1.07B). Analyst consensus is positive with a $59.62 price target, though multiple class action lawsuits create near-term legal overhang. Operating cash flow improved to $1.8B in 2025, supporting ongoing platform investments.
RBLX presents a growth-at-a-value story with robust user monetization potential offset by persistent profitability challenges. The stock offers upside to analyst targets but faces execution risks from legal proceedings and the need to translate revenue growth into sustainable earnings. Investor focus remains on Q3 2026 DAU recovery and margin improvement prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Roblox Corp
Roblox operates an online video game platform that lets young gamers create, develop, and monetize games (or experiences) for other players. The firm effectively offers its developers a hybrid of a game engine, publishing platform, online hosting and services, marketplace with payment processing, and social network. The platform is a closed garden that Roblox controls, earning revenue in multiple places while benefiting from outsourced game development. Unlike traditional video game publishers, Roblox is more focused on the creation of new tools and monetization techniques for its developers then creating new games or franchises. Roblox is increasingly focused on creating a metaverse that moves beyond games toward experiences like concerts, education, and even business management.
Read more on RBLX →
